IL17RA and psoriasis: In our analysis, subtypes A and B exhibited good responses to MTX and IL-12/23 inhibitors (i.e., ustekinumab) and inadequate responses to TNF-α inhibitors (etanercept) and IL-17A receptor (IL-17RA) inhibitors (i.e., brodalumab) compared with subtype C. Collectively, psoriasis molecular subtyping could have an impact on the benefits of drug treatment.